Each programme is shown at the stage it has reached today.
Our most advanced programme is preclinical. No Synthena PDRN programme has entered clinical trials, and no Synthena PDRN medicine has been approved for any indication. The pipeline describes areas of research and development. It does not establish the safety or efficacy of our PDRN in people.
Preclinical
Nearly 9 million new injuries from fire, heat and hot substances occurred worldwide in 2017.
Our most advanced programme is in preclinical development. We are investigating PDRN in burns, difficult-to-heal wounds, ageing skin and hair regrowth.
(Global Burden of Disease Study 2017, Injury Prevention, 2020.)
Research
About 595 million people were living with osteoarthritis worldwide in 2020.
We are investigating PDRN in knee osteoarthritis, tendon injury and delayed bone healing.
Global Burden of Disease Study 2021, The Lancet Rheumatology, 2023.
Research
An estimated 202 million people were living with peripheral artery disease worldwide in 2010.
We are investigating PDRN in impaired circulation of the lower limbs and diabetic foot ulcers.
Fowkes et al., The Lancet, 2013.
Research
More than 6.8 million people were living with inflammatory bowel disease worldwide in 2017.
We are investigating PDRN in inflammatory bowel disease and periodontal disease.
Global Burden of Disease Study 2017, The Lancet Gastroenterology & Hepatology, 2020.
Research
In a population study of adults aged 25–74 in southern Sweden, 3.8% had clinically certain carpal tunnel syndrome.
We are investigating PDRN in carpal tunnel syndrome and persistent neuropathic pain following injury.
Atroshi et al., JAMA, 1999.